By a News Reporter-Staff News Editor at Pain & Central Nervous System Week -- Current study results on Molecular Neurobiology have been published. According to news reporting originating in Shandong, People's Republic of China, by NewsRx journalists, research stated, "Multiple sclerosis is a neurological disorder that presents with symptoms including inflammation, neurodegeneration, and demyelination of the central nervous system (CNS). Secondary progressive multiple sclerosis (SPMS) manifests with serious physical disability."
The news reporters obtained a quote from the research from Shandong University, "To quantitatively analyze differential protein expression in patients with SPMS, we performed two-dimensional fluorescence difference in-gel electrophoresis, followed by mass spectrometry on the cerebrospinal fluid of these patients and patients with other neurological diseases. Vitamin D-binding protein (DBP), gelsolin, albumin, etc. showed more than a 1.5-fold difference between the two groups. Based on these results, an experimental allergic encephalomyelitis (EAE) model of multiple sclerosis in Lewis rats was used to investigate DBP's role in the disease. Protein levels, mRNA transcripts, and ligands of DBP in different regions of the CNS were evaluated under various vitamin D intake levels. Here, DBP levels increased in the experimental rat groups compared to the control groups regardless of vitamin D intake. Moreover, DBP mRNA levels varied in different parts of the CNS including spinal cords in the experimental groups. The observed differences between DBP protein and mRNA levels in the experimental groups' spinal cords could be derived from the disruption of the blood-brain barrier. Furthermore, an interaction between DBP and actin was confirmed using coimmunoprecipitation and western blot. These results indicate a role for DBP in the actin scavenge system. Moreover, in the experimental group that received oral vitamin D3 supplement, we observed both delayed onset and diminished severity of the disease. When DBP was upregulated, however, the benefits from the vitamin D3 supplements were lost. Thus, we inferred that high levels of DBP were adverse to recovery."
According to the news reporters, the research concluded: "Here we observed upregulated DBP in the cerebrospinal fluid could serve as a specific diagnostic biomarker for the progression of multiple sclerosis. Next, we demonstrate the vital function of increased levels of free vitamin D metabolites for multiple sclerosis treatment. Finally, vitamin D supplements may be particularly beneficial for SPMS patients."
For more information on this research see: Vitamin D-binding Protein in Cerebrospinal Fluid is Associated with Multiple Sclerosis Progression. Molecular Neurobiology, 2013;47(3):946-56. Molecular Neurobiology can be contacted at: Springer, 233 Spring Street, New York, NY 10013, USA. (Springer - www.springer.com; Molecular Neurobiology - www.springerlink.com/content/0893-7648/)
Our news correspondents report that additional information may be obtained by contacting M. Yang, Institute of Biochemistry and Molecular Biology, School of Medicine, Shandong University, 44 Wenhuaxi Road, Jinan, Shandong, 250012, People's Taiwan (see also Molecular Neurobiology).
The publisher of the journal Molecular Neurobiology can be contacted at: Springer, 233 Spring Street, New York, NY 10013, USA.
Keywords for this news article include: Asia, Shandong, Neurology, Neurosurgery, Carrier Proteins, Multiple Sclerosis, Demyelinating Diseases, Molecular Neurobiology, Vitamin D Binding Protein, People's Republic of China, Central Nervous System Tumors, Central Nervous System Diseases, CNS Demyelinating Autoimmune Diseases.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC
To see more of the NewsRx.com, or to subscribe, go to http://www.newsrx.com .